RG 7880

Drug Profile

RG 7880

Alternative Names: IL22-Fc; RG7880; RO 7021610; UTTR1147A

Latest Information Update: 19 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Genentech
  • Class
  • Mechanism of Action Interleukin-22 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic foot ulcer; Ulcerative colitis

Most Recent Events

  • 01 May 2016 Phase-I clinical trials in Diabetic foot ulcer (Treatment-experienced) in Spain (SC) (NCT02833389)
  • 01 Apr 2016 Phase-I clinical trials in Ulcerative colitis in Germany (IV) (NCT02749630)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top